Malignant breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention group: In this study, the 177Lu-Trastuzumab PET/CT radiopharmaceutical is injected intravenously into 15 patients with breast cancers according to the 68Ga-Trastuzumab PET/CT. Then whole-
Sponsors
Boushehr University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age =18 years Patients with confirmed HER2-positive breast cancer using 68Ga-Trastuzumab PET/CT Eastern Cooperative Oncology Group Performance Status (ECOG) = 2 Having hematologic parameters as: (i) Absolute neutrophil count = 1000 cells/mm3; (ii) Platelet count = 100,000/mm3; (iii) Hemoglobin = 9 g/dL Signed informed consent form
Exclusion criteria
Exclusion criteria: Pregnant woman Inability to provide written informed consent. Patients with known sensitivity or contraindication to Herceptin. The patient had an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. Patients have psychiatric illness/social situations that would interfere with compliance with study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numbe of treated breast cancer patients. Timepoint: 4-6 weeks after last treatment session. Method of measurement: Image-based response using 68Ga-Trastuzumab PET/CT. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Assadi
Boushehr University of Medical Sciences
Outcome results
None listed